Tien Lee, Aardvark Therapeutics CEO
Aardvark nabs $85M to target hunger, not appetite, as it eyes 2026 NDA filing
A small San Diego biotech wants to take a different approach to the weight loss drug R&D field by going after hunger rather than suppressing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.